Search results for "Research centre"

First moments of the nucleon generalized parton distributions from lattice QCD

2012

We report on our lattice calculations of the nucleon's generalized parton distributions (GPDs), concentrating on their first moments for the case of N_f=2. Due to recent progress on the numerical side we are able to present results for the generalized form factors at pion masses as low as 260 MeV. We perform a fit to one-loop covariant baryon chiral perturbation theory with encouraging results.

Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants:a Prospective Lynch Syndrome Database r…

2021

Purpose: This study aimed to report the uptake of hysterectomy and/or bilateral salpingo-oophorectomy (BSO) to prevent gynaecological cancers (risk-reducing surgery [RRS]) in carriers of pathogenic MMR (path_MMR) variants.Methods: The Prospective Lynch Syndrome Database (PLSD) was used to investigate RRS by a cross-sectional study in 2292 female path_MMR carriers aged 30-69 years.Results: Overall, 144, 79, and 517 carriers underwent risk-reducing hysterectomy, BSO, or both combined, respectively. Two-thirds of procedures before 50 years of age were combined hysterectomy and BSO, and 81% of all procedures included BSO. Risk-reducing hysterectomy was performed before age 50 years in 28%, 25%,…

E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death

2018

International audience; E2F1 is the main pro-apoptotic effector of the pRB-regulated tumor suppressor pathway by promoting the transcription of various pro-apoptotic proteins. We report here that E2F1 partly localizes to mitochondria, where it favors mitochondrial outer membrane permeabilization. E2F1 interacts with BCL-xL independently from its BH3 binding interface and induces a stabilization of BCL-xL at mitochondrial membranes. This prevents efficient control of BCL-xL over its binding partners, in particular over BAK resulting in the induction of cell death. We thus identify a new, non-BH3-binding regulator of BCL-xL localization dynamics that influences its anti-apoptotic activity.

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma : results From the Open-Label, Multicenter, Phase II DAWN Study

2018

Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee–assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle …

Carbon-Coated Anatase TiO2Nanotubes for Li- and Na-Ion Anodes

2014

aInstitute of Physical Chemistry and MEET Battery Research Centre, University of Muenster, 48149 Muenster, Germany bHelmholtz-Institute Ulm (HIU), Electrochemistry I, 89081 Ulm, Germany cKarlsruher Institute of Technology (KIT), 76021 Karlsruhe, Germany dInstitute for Organic Chemistry, University of Mainz, 55128 Mainz, Germany eGraduate School Materials Science in Mainz, 55128 Mainz, Germany fInstitute for Inorganic and Analytical Chemistry, University of Mainz, 55128 Mainz, Germany gMax Planck Institute for Polymer Research, 55128 Mainz, Germany

Measuring Strategies of the Field Experiments CLEOPATRA, FELDEX and NORDEX of the Collaborative Research Centre

2007

Effects of comprehensive geriatric assessment and targeted intervention on mobility in persons aged 75 years and over: a randomized controlled trial

2011

Objective: To assess the effect of a comprehensive geriatric assessment and individually tailored intervention on mobility in older people. In addition, the effectiveness of the geriatric intervention was evaluated among a subgroup of persons with musculoskeletal pain. Design: Three-year geriatric development project with randomized assignment to intervention and control group. Setting: Research centre, community and assisted living facilities. Participants: Seven hundred and eighty-one Finnish persons aged 75–98 years were assigned to an intervention ( n = 404) or control ( n = 377) group. Intervention: A comprehensive geriatric assessment with a multifactorial intervention lasting two ye…

Popular Music and the Anthropocene

2020

International audience; We are at a major turning point, probably irreversible for thousands of years. Despite the continued use of slogans like ‘Save the Planet’, it is living beings, more than the Earth (which has already seen many upheavals) who are threatened with extinction. Although the proponents of the term Anthropocene agree that human activities have become a force that is influencing the geological course of the Earth, and stratigraphers are already finding traces of that process in rocks and sediments (Zalasiewicz 2010), we can however identify two contrasting narratives about the Anthropocene.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale…

2021

BACKGROUND: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials. ESMO-MCBS scores assume valid research methodologies and quality trial implementation. Studies incorporating flawed design, implementation, or data analysis may generate outcomes that exaggerate true benefit and are not generalisable. Failure to either indicate or penalise studies with bias undermines the intention and diminishes the integrity of ESMO-MCBS scores. This review aimed to evaluate the adequacy of the ESMO-MCBS to address bias generated by flawed design, im…

Energy measurements at Skarpnes zero energy homes in Southern Norway: Do the loads match up with the on-site energy production?

2017

Five houses are designed as zero-energy homes in Skarpnes, Norway. The energy goal is to achieve net zero-energy balance on an annual basis. The houses have heat pumps and solar cells (PV). Energy use and delivered energy have been monitored from June 2015. Variations between calculations and measurements are explained by technical and non-technical reasons. For the first year, higher than expected energy loads result in a solar energy cover factor of 65–87% of delivered electricity. The PV generation performs satisfactorily, hence, it may be possible to achieve energy goals during later years provided technical adjustments or behavioral changes. Acknowledgements. This report has been writt…